Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Tyra Biosciences Inc.

Barclays analyst Eliana Merle maintained a Buy rating on Tyra Bioscience today and set a price target of $59.00. Merle covers the Healthcare sector...

Barclays Keeps Their Buy Rating on Tyra Bioscience (TYRA)

Tyra Bioscience ( ($TYRA) ) has shared an update. At its 2026 Annual Meeting of Stockholders held on May 28, 2026, Tyra Biosciences stockholders el...

Tyra Biosciences Shareholders Reelect Directors and Ratify Auditor

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tempus AI, Inc. Class A (TEM), Tyra Bioscience (TY...

Analysts Conflicted on These Healthcare Names: Tempus AI, Inc. Class A (TEM), Tyra Bioscience (TYRA) and BridgeBio Pharma (BBIO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbSci (ABSI), Black Diamond Therapeutics (BDTX) and ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

In a report released today, Jason Zemansky from Bank of America Securities maintained a Buy rating on Tyra Bioscience, with a price target of $37.0...

Bank of America Securities Keeps Their Buy Rating on Tyra Bioscience (TYRA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tyra Bioscience (TYRA) and MDxHealth (MDXH) with bul...

Analysts Offer Insights on Healthcare Companies: Tyra Bioscience (TYRA) and MDxHealth (MDXH)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abeona Therapeutics (ABEO), Protara Therapeutics (TA...

Analysts Are Bullish on These Healthcare Stocks: Abeona Therapeutics (ABEO), Protara Therapeutics (TARA)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on West Pharmaceutical Services (WST), CalciMedica (C...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TYRA	$26.64	-1.99%	1.49M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TYRA	$26.64	-2.0%	1.49M
3
4
5
6

TYRA

TYRA

Get Tyra Biosciences Inc. Data in Excel

Get Tyra Biosciences Inc. Data in Excel